Detalhe da pesquisa
1.
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.
Cost Eff Resour Alloc
; 21(1): 6, 2023 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36647072
2.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562796
3.
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 21(11): 1413-1422, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32979984
4.
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Clin Transl Oncol
; 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38512450
5.
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.
Clin Transl Oncol
; 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38530556
6.
Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review.
Clin Lung Cancer
; 24(3): 185-208, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36907793
7.
Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer.
Cancers (Basel)
; 15(5)2023 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900258
8.
Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer.
Clin Transl Oncol
; 25(11): 3139-3151, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37566345
9.
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
J Clin Oncol
; 41(6): 1200-1212, 2023 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36223558
10.
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective.
Expert Rev Pharmacoecon Outcomes Res
; 22(6): 1033-1042, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35593180
11.
Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Pharmaceuticals (Basel)
; 15(5)2022 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35631359
12.
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program.
Oncotarget
; 13: 812-827, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35720977
13.
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
J Clin Oncol
; 40(25): 2924-2933, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576508
14.
Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab.
Transl Lung Cancer Res
; 10(6): 2509-2522, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34295658
15.
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
J Clin Med
; 10(7)2021 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33810441
16.
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
Clin Cancer Res
; 27(21): 5878-5890, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34376534
17.
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
Clin Transl Med
; 11(7): e491, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34323406
18.
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.
J Immunother Cancer
; 9(8)2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34446577
19.
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy.
Cancers (Basel)
; 12(12)2020 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33322522
20.
The Roles of Imprinted SLC22A18 and SLC22A18AS Gene Overexpression Caused by Promoter CpG Island Hypomethylation as Diagnostic and Prognostic Biomarkers for Non-Small Cell Lung Cancer Patients.
Cancers (Basel)
; 12(8)2020 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32726996